[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gynaecological-malignancies\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gynaecological-malignancies":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,41,77],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100634987","laparotomy-vs-laparoscopy-in-endometrial-cancer-staging-100634987",false,"NCT07546825","Laparotomy vs Laparoscopy in Endometrial Cancer Staging","Perioperative Outcomes of Surgical Staging in Patients With Early-stage Endometrial Carcinoma: Comparison Between Laparoscopy and Laparotomy in a Low-resource Setting","1. Inclusion criteria:\n\n   * Histologically confirmed endometrial carcinoma, diagnosed by endometrial biopsy or dilatation and curettage.\n   * patient candidate for pelvic lymphadenectomy according to risk stratification in endometrial cancer according to ESGO\u002FESTRO\u002FESP, 2021 (6).\n   * Planned surgical staging including: total hysterectomy, bilateral salpingo-oophorectomy ± pelvic lymphadenectomy.\n   * good performance status : ECOG 0, 1, 2\n   * patients who provide informed written consent to participate in the study.\n2. Exclusion criteria:\n\n   * severe cardiopulmonary diseases (e.g unstable angina, severe COPD).\n   * Absolute contraindication to laparoscopy.\n   * stage Ⅲ and Ⅳ endometrial cancer.\n   * patients who received previous pelvic radiotherapy.\n   * patients who underwent prior lymphadenectomy.","FEMALE",{"count":18,"type":19},48,"ESTIMATED","INTERVENTIONAL",[22],"NA","Endometrial cancer is one of the most common gynecological malignancies worldwide. Surgical staging is the cornerstone of management and traditionally performed via laparotomy. However, minimally invasive surgery, particularly laparoscopy, has emerged as an effective alternative with potential benefits in reducing postoperative morbidity.\n\nThis study aims to compare the outcomes of laparoscopic versus open (laparotomy) surgical staging in patients with endometrial cancer in low-resource settings. Primary aim: To compare early postoperative recovery after surgical staging for early-stage endometrial cancer between laparoscopic and open approaches, assessed primarily by time to ambulation.\n\n• Secondary aim: To compare intraoperative outcomes (operative time, blood loss, lymph node yield), postoperative morbidity (Clavien-Dindo classification), quality of recovery (QoR-15), length of hospital stay, same day discharge(SDD), discrepancy between preoperative curettage pathology and final histopathology, delay in initiation of adjuvant therapy, one-year disease-free survival, direct hospital costs between both approaches, and quality of life using EQ-5D-5L questionnaire.\n\nGiven the limited resources and variations in surgical expertise in low-resource settings, this study seeks to evaluate the feasibility, safety, and effectiveness of laparoscopy compared to laparotomy. The findings may help guide clinical decision-making and optimize surgical approaches in similar healthcare environments.",[25,26,27],"Gynaecological Oncology","Gynaecological Malignancies","Laparoscopic","RECRUITING","2026-06-06",{"date":31,"type":32},"2026-06-10","ACTUAL",{"date":34,"type":32},"2026-06-02",{"date":36,"type":19},"2028-10-01",{"name":38,"class":39},"Assiut University","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":20,"phases":53,"briefSummary":54,"conditions":55,"keywords":65,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":40},"100609100","pre-habilitation-within-eras-protocol-for-gynecologic-oncology-surgery-the-preeras-study-100609100","NCT07210164","Pre-habilitation Within ERAS Protocol for Gynecologic Oncology Surgery: The Pre_ERAS Study","Prehabilitation With Exercise and Immunonutrition (Ocoxin®) in the Perioperative Management of Gynecologic Malignancies Under ERAS Protocol.","Pre_ERAS","Inclusion Criteria:\n\n* Type of gynecological malignancy: endometrial cancer, ovarian cancer, cervical cancer, treated with laparotomy after the decision of the gynecological-oncology unit (positive opinion of the Multidisciplinary Tumor Board - MDT)\n* Patient age: 18 to 85 years\n* General condition of the patient: ASA score I-III\n* Consent to implement the accelerated recovery protocol - Enhanced recovery after surgery (ERAS)\n* Sufficient understanding of the Greek language\n* Provision of signed, after thorough information, consent to participate in the study\n\nExclusion Criteria:\n\n* Women with performance status: ECOG \\>2 and ASA score \\>III\n* Women who have not been informed and have given written consent","18 Years","85 Years",{"count":52,"type":19},100,[22],"ERAS (Enhanced Recovery After Surgery) protocols are step-by-step care plans that help patients recover faster after surgery. They focus on keeping the body's normal functions, lowering stress from surgery, and supporting a quicker recovery. In gynecologic cancer surgeries, ERAS has been shown to help patients do better, have fewer problems, and leave the hospital sooner.\n\nA prehabilitation program, in combination with ERAS protocols, aims to optimize patients' physical and psychological condition prior to surgery for gynecological cancers. Interventions may include tailored exercise, nutritional support, respiratory training, and psychological preparation. By enhancing baseline fitness and resilience, prehabilitation improves the body's ability to tolerate surgical stress, reduces complications, and facilitates a faster, smoother recovery within the ERAS framework.",[56,57,58,59,60,61,62,63,26,64,25],"ERAS","Compliance","Quality of Life (QOL)","Excercise","Immunonutrition","Post Operative Pain","Laparotomy Patients","Surgical Complication","Gynaecologic Cancer",[66,56,67,60],"Prehabilitation","Gynecologic Cancers","2025-09-29",{"date":70,"type":32},"2025-10-07",{"date":72,"type":19},"2025-12-01",{"date":74,"type":19},"2029-12-30",{"name":76,"class":39},"Aristotle University Of Thessaloniki",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":20,"phases":87,"briefSummary":89,"conditions":90,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":40},"100508101","phase-2-a-study-of-shr-a1811-in-subjects-with-gynaecologic-oncology-100508101","NCT05896020","A Study of SHR-A1811 in Subjects With Gynaecologic Oncology","Open, Multicenter Phase II Clinical Study of SHR-A1811 for Injection in the Treatment of Gynaecological Malignancies","Inclusion Criteria:\n\n1. The subjects voluntarily joined the study and signed the ICF.\n2. Measurable disease, as defined by RECIST v1.1.\n3. The Eastern Cancer Cooperative Group (ECOG) performance status of 0 or 1.\n4. Life expectancy ≥ 12 weeks.\n5. Subjects with advanced cervical cancer, recurrent ovarian cancer and endometrial cancer.\n\nExclusion Criteria:\n\n1. Symptomatic, untreated or active central nervous system metastases.\n2. Previously received antibo-conjugated drugs with the following characteristics: topoisomerase I inhibition in the composition Preparations, such as Enhertu (DS-8201a), U3-1402, etc..\n3. Have uncontrolled or severe cardiovascular disease.\n4. With any active autoimmune disease or history of autoimmune disease.\n5. Patients with active hepatitis B or hepatitis C.\n6. Severe infections within 28 days prior to initiation of study treatment.\n7. Active tuberculosis within one year prior to initiation of study treatment.","75 Years",{"count":86,"type":19},225,[88],"PHASE2","This is an open-label, two-part study to evaluate the safety and efficacy of SHR-A1811 for injection in subjects with a gynaecological malignancies.",[26],"2023-08-21",{"date":93,"type":32},"2023-08-22",{"date":95,"type":32},"2023-07-10",{"date":97,"type":19},"2026-06-15",{"name":99,"class":100},"Jiangsu HengRui Medicine Co., Ltd.","INDUSTRY"]